Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Regis

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
European Urology Oncology|October 1, 2021
Reply to Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, and Henk van der Poel's Letter to the Editor re: Aina Salazar, Lucas Regis, Jacques Planas, et al. A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. Eur Urol Oncol 2022;5:460-3Juan Morote, Aina Salazar, Lucas Regis
Case Reports in Oncological Medicine|November 3, 2012
Bladder cancer in an inguinoscrotal vesical herniaLucas Regis, Fernando Lozano, Jacques Planas, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 5, 2016
Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapyJuan Morote, Inma Comas, Jacques Planas, et al.
Molecular Diagnosis & Therapy|April 26, 2022
Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic ReviewMíriam Campistol, Juan Morote, Lucas Regis, et al.
Journal of Biomedical Science|October 24, 2017
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patientsJuan Morote, Imma Comas, Roser Ferrer, et al.
European Urology Oncology|March 3, 2021
A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical ProstatectomyAina Salazar, Lucas Regis, Jacques Planas, et al.
The Prostate|November 2, 2016
Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total TestosteroneLucas Regis, Jacques Planas, Joan Carles, et al.
Cancers|October 14, 2022
Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic ReviewMarina Triquell, Miriam Campistol, Ana Celma, et al.
European Urology Open Science|August 2, 2021
Serum Luteinizing Hormone Testing Can Identify Optimal Medical CastrationJuan Morote, Imma Comas, Roser Ferrer, et al.
Clinical Genitourinary Cancer|December 5, 2017
Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist TherapyJuan Morote, Inma Comas, Jacques Planas, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
European Urology Oncology|October 1, 2021
Reply to Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, and Henk van der Poel's Letter to the Editor re: Aina Salazar, Lucas Regis, Jacques Planas, et al. A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. Eur Urol Oncol 2022;5:460-3Juan Morote, Aina Salazar, Lucas Regis
Case Reports in Oncological Medicine|November 3, 2012
Bladder cancer in an inguinoscrotal vesical herniaLucas Regis, Fernando Lozano, Jacques Planas, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 5, 2016
Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapyJuan Morote, Inma Comas, Jacques Planas, et al.
Molecular Diagnosis & Therapy|April 26, 2022
Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic ReviewMíriam Campistol, Juan Morote, Lucas Regis, et al.
Journal of Biomedical Science|October 24, 2017
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patientsJuan Morote, Imma Comas, Roser Ferrer, et al.
European Urology Oncology|March 3, 2021
A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical ProstatectomyAina Salazar, Lucas Regis, Jacques Planas, et al.
The Prostate|November 2, 2016
Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total TestosteroneLucas Regis, Jacques Planas, Joan Carles, et al.
Cancers|October 14, 2022
Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic ReviewMarina Triquell, Miriam Campistol, Ana Celma, et al.
European Urology Open Science|August 2, 2021
Serum Luteinizing Hormone Testing Can Identify Optimal Medical CastrationJuan Morote, Imma Comas, Roser Ferrer, et al.
Clinical Genitourinary Cancer|December 5, 2017
Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist TherapyJuan Morote, Inma Comas, Jacques Planas, et al.
Pageof 4